title: HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Ferretti
authors.forename: Serena
authors.initials: S
authors.lastname: Di Cosimo
authors.forename: Diana
authors.initials: D
authors.lastname: Giannarelli
authors.forename: Paolo
authors.initials: P
authors.lastname: Carlini
authors.forename: Paola
authors.initials: P
authors.lastname: Papaldo
authors.forename: Andrea
authors.initials: A
authors.lastname: Alimonti
authors.forename: Alessandra
authors.initials: A
authors.lastname: Fabi
authors.forename: Mario
authors.initials: M
authors.lastname: Mandalà
authors.forename: Michele
authors.initials: M
authors.lastname: Milella
authors.forename: Enzo Maria
authors.initials: EM
authors.lastname: Ruggeri
authors.forename: Francesco
authors.initials: F
authors.lastname: Cognetti
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017697:Premenopause; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D013629:Tamoxifen